MADRID (Reuters) -Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net ...
Grifols (NASDAQ:GRFS) holder Mason Capital said it's against a potential sale of the Spanish drugmaker to Brookfield Asset ...
Deutsche Bank raised the firm’s price target on Grifols (GRFS) to EUR 10 from EUR 9 and keeps a Hold rating on the shares. Published first on TheFly – the ultimate source for real-time, market-moving ...
Mason Capital Management, a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols (GRFS) class A shares, ...
Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of ...
Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. Shares traded 4.7% higher ...
Brookfield Asset Management is awaiting information from Grifols SA about related-party transactions as it seeks to complete its due diligence on the business, according to a person familiar with ...
Police were called to the scene about 3 p.m. A man was pronounced dead and another was in custody, officials said.
Overview: Grifols, S.A. is a plasma therapeutic company operating in Spain, the United States, Canada, and internationally with a market cap of approximately €6.40 billion. Operations ...
Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasis Grifols surgical bleeding management ...
BARCELONA, Spain, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has ...
Overview: Grifols, S.A. is a plasma therapeutic company operating in Spain, the United States, Canada, and internationally with a market cap of approximately €6.40 billion. Operations: Grifols ...